Who Paid My Doc
Patrick Weyer
Pulmonary Disease Pawtucket, RI Medical Doctor
NPI 1528041324 CMS profile 1004467
111 Brewster St, Department Of Critical Care/ Pulmonary Medicine, Pawtucket, RI 02860
General payments
$175
Research payments
$0
Ownership & investment interest
$0
Through program year 2024, Patrick Weyer of Pawtucket, RI is reported in the CMS Open Payments database as having received $175 across 5 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 19th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
4 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $20 | 1 | |
| 2023 | General | $100 | 1 | |
| 2021 | General | $27 | 2 | |
| 2020 | General | $29 | 1 |
Beside peers
- Patrick Weyer
- Pulmonary Disease median
- Middle half of Pulmonary Disease
- National median
In program year 2025, general payments to Patrick Weyer were reported at $0. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.
Show as a table
| Year | Patrick Weyer | Pulmonary Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $377 | $109–$1,340 | $163 |
| 2020 | $29 | $230 | $56–$907 | $114 |
| 2021 | $27 | $269 | $68–$1,072 | $132 |
| 2022 | $0 | $390 | $100–$1,457 | $149 |
| 2023 | $100 | $419 | $114–$1,659 | $160 |
| 2024 | $20 | $476 | $123–$1,818 | $164 |
| 2025 | $0 | $500 | $124–$1,893 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 25 drugsPart D claims
1,493
Drug cost
$641,954
Branded share of claims
86%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 326 | $232,941 | |
| Ofev Nintedanib Esylate | Brand | 12 | $159,812 | |
| Breo Ellipta Fluticasone/Vilanterol | Brand | 148 | $63,254 | |
| Anoro Ellipta Umeclidinium Brm/Vilanterol Tr | Brand | 53 | $30,741 | |
| Incruse Ellipta Umeclidinium Bromide | Brand | 75 | $27,229 | |
| Stiolto Respimat Tiotropium Br/Olodaterol Hcl | Brand | 26 | $19,847 | |
| Spiriva Respimat Tiotropium Bromide | Brand | 18 | $17,799 | |
| Arnuity Ellipta Fluticasone Furoate | Brand | 64 | $16,511 | |
| Symbicort Budesonide/Formoterol Fumarate | Brand | 53 | $14,893 | |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | Brand | 14 | $11,259 |
The 10 drugs with the highest cost, of 25 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,531 Part D prescribers listed as Critical Care (Intensivists); they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 24 billing codesPaid by Medicare
$54,599
Medicare patients
491
Services billed
976
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 50% | |
| COPD | 42% | |
| Depression | 38% | |
| Ischemic heart disease | 35% | |
| Chronic kidney disease | 35% | |
| Diabetes | 31% | |
| Heart failure | 28% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
5 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pulmonary Disease in Rhode Island
Michael Stanchina
Pulmonary Disease · East Greenwich, RI
William Corrao
Pulmonary Disease · Warwick, RI
Corey Ventetuolo
Pulmonary Disease · Riverside, RI
John Ladetto
Pulmonary Disease · Riverside, RI
Christopher Mullin
Pulmonary Disease · Providence, RI
Raffi Calikyan
Pulmonary Disease · Bristol, RI
Related records
Pulmonary Disease in Rhode Island
Practitioners in the same specialty and state, ranked by reported value.
All Pulmonary Disease
Everyone recorded under this specialty, nationwide.
Doctors in Rhode Island
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.